TP53 and cancer: Notably, Trp53(R245W/R245W) tumours exhibited lower levels of a number of immune responses specifically relevant to cancers, compared with the Trp53(+/+), Trp53(−/−) or the Trp53(R172H/R172H) counterparts; examples include: inflammatory response; TNF-Alpha signalling via NFK-Beta; IFN-Gamma response; IFN-Alpha response; and IL6-JAK-STAT3 signalling (Fig. 6c).